Adaptogen herbal supplement
Rhodiola Rosea
The EU assessment report on Rhodiola rosea gives "No data published" for the pharmacokinetics of its preparations; the app lists a half-life of 5 hours.1
Rhodiola Rosea after one dose: 50% at ~5 h, 25% at 10 h, 12.5% at 15 h.
Drawn from the half-life in the app's model, ~5 h. The model's figures
- Compound
- Rhodiola Rosea
- Symbol
- RHO
- Family
- Supplements
- Parts
- 13
- References
- 11
- Checked
- Last reviewed . Sources are listed below.
Overview
Rhodiola rosea is a plant whose root and rhizome are used in herbal preparations, and the European Union lists it as a traditional herbal medicinal product.2 The monograph describes a dry extract (DER 1.5-5:1) in solid oral dosage forms, and states that the indication rests "exclusively based upon long-standing use".2 The European Medicines Agency's Committee on Herbal Medicinal Products first adopted a monograph on 27 March 2012, and a revised monograph is dated 20 March 2024.3,2
The app lists Rhodiola rosea as an adaptogen supplement, and its notes describe a product standardised to 3% rosavins and 1% salidroside. The trial extracts differed from that description: the extract in Mao and colleagues' trial was standardised "to a content of rosavin 3.07%/rhodioloside 1.95%", and the extract in the Alberta trial to 2.8% total rosavins.4,5 The Alberta trial authors write that "most preparations are standardized to one or both of two compounds" (rosavin and salidroside), and that there is "lack of clarity around which specific compounds are considered active constituents".5
The app grades the evidence for Rhodiola rosea as moderate. The European Medicines Agency's 2011 assessment report states that "The published clinical trials exhibit considerable deficiencies in their quality" and that "there is not sufficient evidence for a clinical efficacy of herbal preparations of Rhodiola rosea for the treatment of symptoms of fatigue or mental weakness".1 The same report accepts the traditional-use indication on the basis of long use, noting that dry extracts have been in medicinal use in the European Union since 1987.1 A 2011 systematic review (Hung and colleagues, Phytomedicine) included 11 randomised trials, "all were placebo-controlled", and concluded that "There is, however, a lack of independent replications of the single different studies."6
How it works
Sources in this part
Human mechanism data are limited in the sources read, and the EU assessment report cautions about the laboratory literature: "in many of the experiments supraphysiological concentrations or dosages far exceeding the proposed dose in humans were applied".1 The same report states that results from isolated constituents "suggest that the phenylethanoids like salidroside contribute to these effects", which refers to animal and laboratory models of anti-fatigue and stress-protective effects, not to a measured effect in people.1 The introduction to the Mao trial states that, in in-vitro bioassay studies, the extract "has also been shown to inhibit monoamine oxidase A and B enzymes"; that is a laboratory finding quoted from the authors' background, and the trial itself did not measure it.4
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~5 h
- Bioavailability
- 60%
- Typical dose
- 200–600 mg/day
- Route
- Oral
- Time to peak
- ~2 h
Sources in this part
The second column holds the app's figures, shown beside what the sources report.
| Parameter | App's figure | Reported in the sources |
|---|---|---|
| Half-life | ~5 h | The 2011 EU assessment report gives "No data published" for pharmacokinetic data on the herbal substance, preparations and constituents.1 The 2024 EU monograph gives "Not required" for its pharmacokinetic section.2 No human half-life figure for any Rhodiola rosea constituent appeared in the sources read. |
| Bioavailability | 60% | None of the sources read gives an oral bioavailability figure for rosavins, salidroside or an extract. |
| Time to peak | ~2 h | None of the sources read gives a time to peak for any Rhodiola rosea constituent in people. |
| Duration of effect | 8 h | None of the sources read gives a duration of effect. |
The only pharmacokinetic work the EU assessment report describes is in vitro and in rats: six Norwegian clones inhibited CYP3A4 and P-gp activity in laboratory assays, and in Wistar rats given 50 mg/kg daily for 3 days the extract did not alter the pharmacokinetics of warfarin or theophylline.1
Human studies
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Olsson and colleagues, Planta Medica 20097 | Phase III, randomised, double-blind, placebo-controlled, parallel groups | 60 adults aged 20 to 55 with fatigue syndrome by Swedish criteria; 30 per group | SHR-5 extract, four tablets daily (576 mg extract/day); 28 days | Placebo groups and treatment group both improved; between-group differences were reported on Pines' burnout scale and three attention indices, and in cortisol response to awakening; no serious side effects attributed to the extract |
| Punja and colleagues, PLoS One 20145 | Parallel-group randomised, double-blind, placebo-controlled; funded by the Government of Alberta | 48 randomised (24 and 24) nursing students on shift work; 40 analysed | 364 mg capsule(s) with up to one more capsule in the following four hours; 42 days | Fatigue scores differed "in favor of placebo": Vitality-subscale -17.3 (95% CI -30.6, -3.9), p = 0.011; adverse events did not differ between groups |
| Mao and colleagues, Phytomedicine 20154 | Phase II randomised, double-blind, three arms (extract, sertraline, placebo); NIH-funded | 57 randomised (20, 19 and 18) adults with mild to moderate major depressive disorder | SHR-5 extract 340 mg capsules, 1 to 4 capsules daily by dose escalation; 12 weeks | No significant difference between groups on HAM-D (p = 0.79), BDI (p = 0.28) or CGI/C (p = 0.17); adverse events in 30.0% on extract, 63.2% on sertraline, 16.7% on placebo |
| Cropley and colleagues, Phytotherapy Research 20158 | Randomised, no-treatment control (not placebo-controlled) | 80 mildly anxious participants | 2 × 200 mg tablets daily (one before breakfast, one before lunch); 14 days | Self-reported anxiety, stress, anger, confusion and depression fell relative to controls; no relevant differences in cognitive performance |
| Thu and colleagues, European Journal of Clinical Pharmacology 20169 | Randomised cross-over, with and without pretreatment | 13 healthy volunteers | Commercial Rhodiola rosea product (Arctic Root); 14 days of pretreatment | 21% decrease in the EXP-3174/losartan ratio (p = 0.023), a CYP2C9 measure; no significant effects for the other CYP enzymes tested |
| Hung and colleagues, Phytomedicine 20116 | Systematic review of randomised trials of single-herb oral Rhodiola rosea preparations | 11 placebo-controlled trials; the record's breakdown (six on physical performance, four on mental performance, two in patients with a mental health condition) sums to 12 and a later sentence refers to 10 RCTs | Not summarised in the record read | Authors conclude Rhodiola rosea "may have beneficial effects", note a lack of independent replications and state "More research seems warranted"; "Only few mild adverse events were reported" |
Searches of PubMed and ClinicalTrials.gov on 16 November 2026 returned further Rhodiola rosea trials (42 and 29 records respectively), including exercise-performance, eye-strain and combination-product trials; they are not summarised here.
Deeper analysis: the Alberta nursing-student trial (Punja and colleagues, PLoS One, 2014)
Punja and colleagues, working at the University of Alberta and the Ottawa Hospital Research Institute, randomised 48 nursing students on shift work, 24 to Rhodiola rosea and 24 to placebo, in a parallel-group, double-blind trial.5 The extract was standardised to 2.8% total rosavins, and participants took 364 mg at the start of their wakeful period plus up to one more capsule in the following four hours for 42 days; the authors report daily doses of 364 to 546 mg, with most participants taking 364 mg.5 The primary outcome was fatigue on the RAND-36 Vitality-subscale, cross-validated by a visual analogue scale for fatigue.5 The result favoured placebo: "The mean change in scores on the VAS-F was also significantly difference between study groups at day 42 in favour of placebo (1.9 (95% CI 0.4, 3.5), p = 0.015)".5 Of the other seven RAND-36 subscales, only general health differed between groups, in favour of placebo (-13.4, 95% CI -24.6, -2.3, p = 0.018), and none of the changes on the MYMOP were statistically significant.5 The authors' conclusion is that a 42-day course of the extract, compared with placebo, "worsened fatigue", and they urge caution in interpreting this.5 Six people dropped out before treatment (three in each arm) and two were withdrawn, leaving 40 in the analysis (21 on the extract, 19 on placebo).5 Adverse events numbered 10 in six participants on the extract and 10 in six participants on placebo, and the authors state "All adverse events were categorized as mild to moderate"; headache was recorded 4 times in 3 participants on the extract and 2 times in 1 participant on placebo.5 On the extract the table also lists diarrhea/nausea (2 events, 1 participant), dark stool (2 events, 1 participant), nausea (1, 1) and blurred vision (1, 1); on placebo it lists light headedness (2 events, 2 participants), nosebleed (2, 1), and single events of excess energy, heartburn, heart palpitations and sore throat.5 The authors list their own limitations: "The intended sample size of 64 participants was not achieved due to a short funding period and subsequent challenges with recruitment", and the smaller sample "left our study vulnerable to potential imbalances in important baseline demographics between the two study groups".5 They also write that the dose "was not sufficient to see an effect" is another possible explanation, and that more severely fatigued patients might show an effect "less apparent in a healthier population"; the study "was not powered to detect meaningful differences" in adverse events.5 The funding statement reads: "This project was funded by the Alberta Agriculture and Rural Development, Government of Alberta, through AVAC Ltd. The funder developed and prepared the trial intervention, but had no role in the design and conduct of the study".5 The registry entry (NCT01278992) names the Government of Alberta as lead sponsor, lists the trial as phase 2 with an estimated enrolment of 90, and its status as unknown, last verified in February 2011.10
Deeper analysis: the Rhodiola rosea versus sertraline trial (Mao and colleagues, Phytomedicine, 2015)
Mao and colleagues, at the University of Pennsylvania Perelman School of Medicine, ran a 12-week proof-of-concept trial in adults with a DSM-IV diagnosis of major depressive disorder of mild to moderate severity, with 57 randomised to the extract (n=20), sertraline (n=19) or placebo (n=18).4 The extract was SHR-5 340 mg capsules (rosavin 3.07%, rhodioloside 1.95%), sertraline was 50 mg capsules, and dosing began at one capsule daily and was escalated up to four capsules daily according to response.4 HAM-D declines by week 12 were -8.2 (95% CI -12.7 to -3.6) for sertraline, -5.1 (95% CI -8.8 to -1.3) for the extract and -4.6 (95% CI -8.6 to -0.6) for placebo, with no significant difference between groups on HAM-D, BDI or CGI/C (p = 0.79, 0.28 and 0.17).4 The discussion states "While overall efficacy did not differ from that of placebo", and the odds of global improvement against placebo were 1.39 (0.38-5.04) for the extract and 1.90 (0.44-8.20) for sertraline.4 The authors also write that they "found clinically meaningful (albeit non-significant) reductions over time in HAM-D scores for both R. rosea extract and sertraline", and their conclusion is that the findings "suggest that R. rosea may possess modest antidepressant effects in some patients with mild to moderate MDD".4 Adverse events were reported by 30.0% on the extract, 63.2% on sertraline and 16.7% on placebo (p = 0.012); on the extract, nervousness and dizziness were each recorded in 2 participants, and the paper reports "There were no treatment-related serious adverse events".4 By week 8, 13 participants (22.8%) had discontinued treatment: 2 because of adverse events (both in the sertraline group), 1 who withdrew consent, 6 lost to follow-up and 4 who ended participation because of lack of efficacy.4 The authors state limitations including that the study "was designed to generate preliminary efficacy and safety data to determine sample size estimates for a future, fully-powered study", that "the sertraline group had slightly higher HAM-D scores at baseline", and that because of the dose-escalation design they "were unable to determine whether or not there might be a dose-response relationship".4 The trial was supported by an NCCAM grant (R21 AT005230) and the Jack Warsaw Fund for Research in Biological Psychiatry; the Swedish Herbal Institute supplied the extract and "had no role in design, conduct or report of the study", and the authors state they have no financial interest in any pharmaceutical or herbaceutical company.4
Deeper analysis: the SHR-5 stress-related fatigue trial (Olsson and colleagues, Planta Medica, 2009)
Only the PubMed record of this trial was read, so the points below come from that record and not from the full paper. Olsson and colleagues (first author at the Department of Psychology, Uppsala University) report a phase III, randomised, double-blind, placebo-controlled trial of 60 adults aged 20 to 55 selected on Swedish diagnostic criteria for fatigue syndrome, 30 per group.7 Outcomes were measured on day 1 and after 28 days of medication, including burnout (Pines' scale), depression (MADRS), attention and saliva cortisol response to awakening.7 The record states that both groups improved: "Significant post-treatment improvements were observed for both groups (placebo effect)" on the burnout scale, SF-36 mental health, MADRS and several attention indices.7 Between groups, significant effects were reported on the burnout scale and on the attention indices omissions, Hit RT SE and variability, and the cortisol response to awakening differed between the groups; the record does not list a between-group difference on the MADRS or SF-36.7 The record states "No serious side effects that could be attributed to the extract were reported", and the EU assessment report adds that "No data on non-serious side effects are mentioned in the publication".7,1 The record read does not state the authors' limitations, the funder or the co-authors' ties to the extract's maker; its publication-type line lists "Research Support, Non-U.S. Gov't".7 The Mao paper obtained SHR-5 from the Swedish Herbal Institute and thanks Alexander Panossian, PhD of that institute, for help with US approval of the extract; the Olsson record lists Panossian Alexander G among its authors, without an affiliation.4,7
Deeper analysis: the Vitano extract trial (Cropley and colleagues, Phytotherapy Research, 2015)
Cropley and colleagues, at the School of Psychology, University of Surrey, randomised 80 mildly anxious participants to two 200 mg tablets of Vitano daily or to no treatment, with testing sessions over 14 days.8 The authors report significant reductions in self-reported anxiety, stress, anger, confusion and depression at 14 days and "No relevant differences in cognitive performance between the groups".8 They state "Although this was a non-placebo controlled trial" and "we cannot determine a causal relationship", and describe a "favourable safety tolerability profile" for the extract.8 The record read does not state the funder or any author tie to the product's maker; the publication-type line lists "Research Support, Non-U.S. Gov't".8
Doses reported in studies and on labels
The app's typical range is 200 to 600 mg/day. The EU monographs describe a dry extract with a drug-extract ratio (DER) of 1.5-5:1; the 2011 assessment report lists SHR-5 among the preparations (DER 2.5-5:1, ethanol 70% as first extraction solvent), while the trial extracts above are described by marker content or product name.2,1
| Source | Dose reported | Preparation, people and length |
|---|---|---|
| EU herbal monograph, 20242 | Single dose 144-200 mg, 1-2 times daily; daily dose 144-400 mg | Dry extract (DER 1.5-5:1, ethanol 67-70% V/V), oral; adults and elderly; use under 18 years is not recommended; the duration-of-use entry refers to a doctor or qualified health care practitioner if symptoms persist longer than 2 weeks |
| Community herbal monograph, 2012 (superseded)3 | Single dose 144-200 mg; daily dose 144–400 mg | Same dry extract description; adults and elderly |
| Olsson and colleagues, 20097 | 576 mg extract/day (four tablets) | SHR-5 extract; 30 adults with fatigue syndrome; 28 days |
| Punja and colleagues, 20145 | 364 mg, plus up to one more capsule within four hours; reported daily doses 364–546 mg | Extract standardised to 2.8% total rosavins; 24 nursing students on shift work (21 analysed); 42 days |
| Mao and colleagues, 20154 | 340 mg capsules, one daily rising to up to four by response | SHR-5 extract; 20 adults with mild to moderate major depressive disorder; 12 weeks |
| Cropley and colleagues, 20158 | 2 × 200 mg tablets daily | Vitano extract; 80 mildly anxious participants randomised to the extract or to no treatment (group sizes not given in the record read); 14 days |
The app's high figure of 600 mg/day is above the EU monograph's daily dose of 144-400 mg and above the 576 mg/day used by Olsson and colleagues; a sertraline-comparison trial escalated up to four 340 mg capsules daily.2,7,4
Side effects reported
The 2024 EU monograph lists headache (nervous system disorders), nausea, abdominal pain and diarrhoea (gastrointestinal disorders), and skin rash and itching (skin disorders), each with "The frequency is not known".2 The 2012 monograph gave "None known" for undesirable effects, and the 2011 assessment report states that the registered products' summaries of product characteristics also mention hypersensitivity reactions and hypoglycaemia.3,1 The assessment report notes dizziness and dry mouth after 340 mg of extract daily in the Bystritsky study, and concludes "The reported adverse events are mild".1 In the trials above, adverse events were reported by 6 of 20 participants on the extract in the sertraline-comparison trial, and 10 events in six participants on the extract against 10 events in six on placebo in the nursing-student trial.4,5 The EU assessment report states that there are no published case reports of overdose and that no studies on the effect on the ability to drive and use machines have been published; for pregnancy and lactation it gives "No data published", and the 2024 monograph states "Safety during pregnancy and lactation has not been established. In the absence of sufficient data, the use during pregnancy and lactation is not recommended."1,2
Bloodwork and markers
The app lists no markers to monitor for Rhodiola rosea. In the sertraline-comparison trial, laboratory values were checked at baseline and the paper states "No significant changes were observed in any laboratory values for any treatment group", with no clinically meaningful differences in blood pressure, pulse rate or weight in the extract or sertraline groups.4 In the stress-related fatigue trial, saliva cortisol response to awakening was measured and differed between the treatment and control groups.7 Thu and colleagues (Norwegian University of Science and Technology and St. Olav University Hospital) gave 13 healthy volunteers a drug cocktail with and without 14 days of a commercial product, and reported a 21% decrease in the EXP-3174/losartan ratio (p = 0.023), "indicating a reduced CYP2C9 metabolic activity", with no significant effects on CYP1A2, CYP2C19, CYP2D6 or CYP3A4 measures.9 The authors write that "The effect was more pronounced in CYP2C9 extensive metabolizers than in CYP2C9 intermediate and poor metabolizers" and that "Although the effect is modest, it might be clinically relevant during treatment with CYP2C9 substrates with a narrow therapeutic index, such as phenytoin and warfarin".9 The product tested was made by the Swedish Herbal Institute; the record read does not state the study's funder.9 The EU documents differ on interactions: the 2012 monograph gave "None reported", the 2011 assessment report states "Neither clinical data nor case reports on interactions are published", and the 2024 monograph states "No clinically relevant interactions have been observed."3,1,2
Regulatory and anti-doping status
The European Union monograph classes Rhodiola rosea dry extract as a traditional herbal medicinal product based on long-standing use, with an indication for relief of symptoms of stress such as fatigue and exhaustion.2 The 2011 assessment report states that "well-established use" could not be accepted because of deficiencies in the published trials.1 The 2024 monograph gives "Hypersensitivity to the active substance" as its contraindication and states that "Tests on reproductive toxicity, genotoxicity and carcinogenicity are not available".2 The text of the World Anti-Doping Agency's 2026 Prohibited List, searched for "rhodiola", does not contain the word.11
What is not known
No human pharmacokinetic figure (half-life, bioavailability, time to peak or duration) for rosavins, salidroside or a Rhodiola rosea extract was identified in the sources read, so the app's 5 hours, 60%, 2 hours and 8 hours have no figure from the sources beside them.1 The trials differ in extract (SHR-5, Vitano, an Alberta-grown extract), dose, population and comparator, and their results point in different directions: an improvement over placebo on some measures in one trial, a result in favour of placebo in another, and no significant difference from placebo in a third.7,5,4 The Alberta trial authors suggest the dose may have been too low, and the sertraline-comparison authors state their dose-escalation design left a dose-response relationship undetermined, so the relation between dose and effect is not established in the sources read.5,4 The longest trial summarised here lasted 12 weeks, and the Mao authors note that longer studies are needed to assess durability.4 The app's notes describe Rhodiola rosea as a "non-sedating" alternative to ashwagandha; a PubMed query for "Rhodiola rosea ashwagandha" returned 43 records, and none of the 20 titles shown was a head-to-head trial of the two as single agents.
Frequently asked questions
What is the half-life of Rhodiola rosea?
What is the bioavailability of Rhodiola rosea?
None of the sources read gives an oral bioavailability figure, and the app lists 60%.1
Is Rhodiola rosea banned by WADA?
The text of the 2026 WADA Prohibited List does not contain the word "rhodiola".11 The search covered that list text only, not any product label or contamination testing.
Is Rhodiola rosea recognised by the European Medicines Agency?
The EU herbal monograph (revision 1, 20 March 2024) classes Rhodiola rosea dry extract as a traditional herbal medicinal product based on long-standing use.2 The 2011 assessment report states that the trials had "considerable deficiencies in their quality" and that "well-established use" could not be accepted.1
Did Rhodiola rosea reduce fatigue in clinical trials?
Results differ between trials. In the Olsson trial of 60 adults with fatigue syndrome, the extract differed from placebo on the burnout scale and some attention indices after 28 days, while both groups improved on several measures.7 In the Alberta trial of nursing students on shift work, fatigue scores favoured placebo (Vitality-subscale -17.3, 95% CI -30.6 to -3.9, p = 0.011), and the authors urge cautious interpretation.5
Did Rhodiola rosea beat placebo for depression in a trial?
In a 57-person, 12-week phase II trial in mild to moderate major depressive disorder, there was no significant difference between groups on HAM-D (p = 0.79).4 HAM-D fell by 5.1 points on the extract, 8.2 on sertraline and 4.6 on placebo, and the authors call the study a proof-of-concept trial not powered for small differences.4
What side effects of Rhodiola rosea have been reported?
Does Rhodiola rosea interact with other drugs?
In a crossover study of 13 healthy volunteers, 14 days of a commercial product was followed by a 21% decrease in the EXP-3174/losartan ratio, a CYP2C9 measure (p = 0.023).9 The authors reported no significant effects for the other CYP enzymes tested and conclude that the effect is modest but "it might be clinically relevant during treatment with CYP2C9 substrates with a narrow therapeutic index, such as phenytoin and warfarin", while the 2024 EU monograph states "No clinically relevant interactions have been observed."9,2
Is Rhodiola rosea established as safe in pregnancy?
The 2024 EU monograph states that "Safety during pregnancy and lactation has not been established. In the absence of sufficient data, the use during pregnancy and lactation is not recommended."2
Guides, tools and comparisons
References
- European Medicines Agency, Committee on Herbal Medicinal Products. Assessment report on Rhodiola rosea L., rhizoma et radix. EMA/HMPC/232100/2011, 2011. EMA assessment report
- European Medicines Agency, Committee on Herbal Medicinal Products. European Union herbal monograph on Rhodiola rosea L., rhizoma et radix, Final, Revision 1. EMA/HMPC/24177/2023, 20 March 2024. EU herbal monograph (2024)
- European Medicines Agency, Committee on Herbal Medicinal Products. Community herbal monograph on Rhodiola rosea L., rhizoma et radix. EMA/HMPC/232091/2011, 27 March 2012 (superseded). Community herbal monograph (2012)
- Mao JJ, et al. Rhodiola rosea versus sertraline for major depressive disorder: a randomized placebo-controlled trial. Phytomedicine 2015. PMID 25837277
- Punja S, et al. Rhodiola rosea for mental and physical fatigue in nursing students: a randomized controlled trial. PLoS One 2014. PMID 25268730
- Hung SK, et al. The effectiveness and efficacy of Rhodiola rosea L.: a systematic review of randomized clinical trials. Phytomedicine 2011. PMID 21036578
- Olsson EM, et al. A randomised, double-blind, placebo-controlled, parallel-group study of the standardised extract SHR-5 of the roots of Rhodiola rosea in the treatment of subjects with stress-related fatigue. Planta Med 2009. PMID 19016404
- Cropley M, et al. The effects of Rhodiola rosea L. extract on anxiety, stress, cognition and other mood symptoms. Phytother Res 2015. PMID 26502953
- Thu OK, et al. Effect of commercial Rhodiola rosea on CYP enzyme activity in humans. Eur J Clin Pharmacol 2016. PMID 26613955
- Government of Alberta. Rhodiola Rosea for Mental and Physical Fatigue. ClinicalTrials.gov NCT01278992. NCT01278992
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list